Drug intelligence / Profile preview

TBE001-A-S033

Development stage: Preclinical
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Peptides
Administration: Subcutaneous

Overview

TBE001-A-S033 is a long-acting insulin analog designed for once-weekly administration in the treatment of type 2 diabetes mellitus (T2DM). Developed as a modification of insulin icodec, it features a modified acylation side chain to optimize its pharmacokinetic profile and prolong blood glucose control. In preclinical studies using ICR and db/db mice, the compound demonstrated a favorable hypoglycemic effect and a species-dependent half-life comparable to or improved over insulin icodec, suggesting its potential as a weekly therapeutic option for glycemic management.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on TBE001-A-S033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBE001-A-S033.

Explore the full profile